ДЕНСАУЛЫҚ САҚТАУ ҰЙЫМЫ
ОРГАНИЗАЦИЯ ЗДРАВООХРАНЕНИЯ
HEALTH ORGANIZATION

УДК: 615.38:616-036.21-082
DOI: 10.26212/2227-1937.2023.79.70.005
Received: 1 june 2023/ Accepted: 29 june 2023 / Published online: 01july 2023

Maral A. Yerdenova[1], https://orcid.org/0000 - 0002 - 4375-9506
Aigulsum K. Izekenova[1], https://orcid.org/0000-0003 - 3850-8689
Akbope K. Myrkassymova[1], https://orcid.org/0000-0002-2134-2494
Gaukhar A. Mergenova[1,2], https://orcid.org/0000-0003-4702-1944
[1]Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan
[2]Global Health Research Center of Central Asia, Almaty, Kazakhstan

SCIENTIFICALLY SUBSTANTIATED APPROACHES TO THE ORGANIZATION OF HEMATOLOGICAL CARE IN THE CONTEXT OF THE COVID-19 PANDEMIC: A COMPREHENSIVE REVIEW

Resume: The COVID-19 pandemic has presented significant challenges to healthcare systems worldwide, particularly affecting patients with non-communicable diseases like hematological disorders. These patients are often immunocompromised and require continuous care, making it crucial to maintain service provision during health crises.
The aim is to study the effectiveness and adaptability of various methods in organizing medical aid for hematological patients in the context of the COVID-19 pandemic, considering the research and practical approaches from different regions of the world.
Materials and methods: This study employs a literature review methodology, systematically analyzing scholarly articles from multiple databases, including PubMed, Scopus, and Web of Science. The articles were selected based on specific inclusion and exclusion criteria, focusing on those published between 2020 and 2023 that discuss the organization of hematological care during the COVID-19 pandemic.
Results: The results demonstrate a global consensus on the importance of adaptive strategies for managing hematological care amidst the pandemic. Telemedicine has been widely adopted, providing continuity of care, though challenges persist. Triage protocols were developed to prioritize vulnerable patients, and convalescent plasma therapy emerged as a promising treatment for high-risk groups. Personalized treatment strategies, considering individual risk assessments and the need to limit immunosuppressive effects, were also prevalent in the reviewed literature.
Conclusion: The COVID-19 pandemic has necessitated novel, scientifically grounded approaches to organize effective hematological care. Despite the challenges, the healthcare community's global efforts underscore the resilience and innovation in health systems. Insights drawn from this study can inform ongoing and future responses to health crises, thereby ensuring continuity and quality of care for hematological patients.
Keywords: COVID-19, hematological patients, telemedicine, triage protocols, convalescent plasma therapy, personalized treatment strategies, pandemic response, healthcare organization.

Марал А. Ерденова[1], https://orcid.org/0000-0002-4375-9506
Айгульсум К. Изекенова[1], https://orcid.org/0000-0003 - 3850-8689
Акбопе К. Мыркасымова[1], https://orcid.org/0000-0002-2134-2494
Гаухар А. Мергенова[1,2], https://orcid.org/0000-0003-4702-1944
[1]НАО Казахский национальный медицинский университет им. С.Д. Асфендиярова, г.Алматы, Республика Казахстан;
[2]Центр Изучения Глобального здоровья в Центральной Азии, г.Алматы, Республика Казахстан

НАУЧНО-ОБОСНОВАННЫЕ ПОДХОДЫ К ОРГАНИЗАЦИИ МЕДИЦИНСКОЙ ПОМОЩИ ПАЦИЕНТАМ ГЕМАТОЛОГИЧЕСКОГО ПРОФИЛЯ В УСЛОВИЯХ ПАНДЕМИИ COVID-19

Резюме: Пандемия COVID-19 представляет значительные вызовы для систем здравоохранения во всем мире, особенно влияя на пациентов с неинфекционными заболеваниями, такими как гематологические расстройства. Эти пациенты часто имеют сниженный иммунитет и требуют непрерывного ухода, что делает важным поддержание предоставления услуг во время кризисов в области здравоохранения.
Цель исследования состоит в изучении эффективности и адаптивности различных методов организации медицинской помощи гематологическим пациентам в контексте пандемии COVID-19, учитывая исследования и практические подходы из разных регионов мира.
Материалы и методы: В данном исследовании используется методика обзора литературы, систематически анализируя научные статьи из нескольких баз данных, включая PubMed, Scopus и Web of Science. Статьи были отобраны на основе конкретных критериев включения и исключения, сосредоточиваясь на тех, которые были опубликованы между 2020 и 2023 годами и обсуждают организацию гематологического ухода во время пандемии COVID-19.
Результаты: Результаты демонстрируют мировой консенсус относительно важности адаптивных стратегий для управления гематологическим уходом в условиях пандемии. В рассмотренной литературе также широко представлены персонализированные стратегии лечения, учитывающие индивидуальные оценки риска и необходимость ограничить иммуносупрессивные эффекты.
Заключение: Пандемия COVID-19 потребовала новых, научно-обоснованных подходов к организации эффективного ухода за пациентами с гематологическими заболеваниями. Несмотря на вызовы, глобальные усилия сообщества

здравоохранения подчеркивают устойчивость и инновационность в системах здравоохранения. Выводы, полученные в этом исследовании, могут информировать текущую и будущую реакцию на кризисы в области здравоохранения, обеспечивая непрерывность и качество ухода за гематологическими пациентами.
Ключевые слова: COVID-19, гематологические пациенты, телемедицина, протоколы триажа, терапия конвалесцентной плазмой, персонализированные стратегии лечения, реакция на пандемию, организация здравоохранения.

COVID-19 ПАНДЕМИЯСЫ ЖАҒДАЙЫНДА ГЕМАТОЛОГИЯЛЫҚ НАУҚАСТАРҒА МЕДИЦИНАЛЫҚ КӨМЕКТІ ҰЙЫМДАСТЫРУДЫҢ ҒЫЛЫМИ НЕГІЗДЕРІ

Марал А. Ерденова[1], https://orcid.org/0000-0002-4375-9506
Айгульсум К. Изекенова[1], https://orcid.org/0000-0003 - 3850-8689
Акбопе К. Мыркасымова[1], https://orcid.org/0000-0002-2134-2494
Гаухар А. Мергенова[1,2], https://orcid.org/0000-0003-4702-1944
[1]«С.Ж. Асфендияров атындағы Қазақ Ұлттық медицина университеті» КеАҚ, Алматы қ., Қазақстан Республикасы
[2]Орталық Азиядағы жаһандық денсаулықты зерттеу орталығы Алматы қ., Қазақстан Республикасы.

Түйін: COVID-19 пандемиясы дүниежүзілік денсаулық жүйесіне бір мезетте мәселелер мен мүмкіндіктер алып келіп, гематологиялық аурулардың зерттелуі әдістеріне жаңа өзгерістер енгізді. Зерттеу мақаласында пандемия кезіндегі гематологиялық қызмет ұйымдастыру қызметі мен емдеу стратегиялары зерттеліп, соңғы үш жыл көлеміндегі жарияланған ғылыми зерттеу жұмыстарына әдеби талдау жасалынады.
Зерттеу мақсаты COVID-19 пандемиясы кезіндегі гематологиялық пациенттерге медициналық көмек ұйымдастыруда түрлі әдістердің әсері мен бейімділігін зерттеу.
Материалдар мен әдістер: Бұл зерттеуде әдебиеттерге шолу әдісі қолданылады, атап айтар болсақ PubMed, Scopus және Web of Science деректер қорларынан әр түрлі ғылыми мақалаларды жүйелі түрде талдау. Мақалалар көрсетілген қосымша және шығару критерийлері бойынша таңдалып алынып,COVID-19 пандемиясы кезіндегі гематологиялық қызмет ұйымдастыру туралы жарияланған 2020 және 2023 жылдар аралығындағы мақалаларды ұсынылған. Аталмыш зерттеу жұмыстарына салыстырмалы зерттеу жүргізілді.
Нәтижелер: Пандемия қарсаңындағы гематологиялық қызметті ұйымдастыруда адаптивті стратегиялардың маңыздылығы туралы әдебиеттерге ортақ анализ жасалынып, анықталды.
Қорытынды COVID-19 пандемиясы гематологиялық қызмет ұйымдастыруда жаңа, ғылыми негіздеген тәсілдерді қажет етті.
Түйінді сөздер: COVID-19, гематологиялық науқастар, реконвалесцентті плазмалық терапия, жекелендірілген емдеу стратегиялары, пандемияға қарсы әрекет, денсаулық сақтау ұйымы.

Introduction: The COVID-19 pandemic has exerted unprecedented pressure on healthcare systems worldwide, posing unique challenges for medical practitioners, particularly those dealing with patients suffering from hematological diseases. The COVID-19 pandemic, caused by the novel SARS-CoV-2 virus, has significantly disrupted healthcare systems globally. This impact has been particularly acute in the care of patients with hematological disorders. These patients often require ongoing and intricate medical support, and their conditions may render them more susceptible to severe COVID-19 outcomes. The literature on the intersection of the COVID-19 pandemic and hematological healthcare provides insights into the strategies and practices that optimize patient care under such extraordinary circumstances. This literature review aims to critically analyze and synthesize the prevailing scientific knowledge on the topic, thereby identifying potential areas for further investigation. The emergence of new epidemiological threats globally, such as COVID-19, has necessitated a reassessment of scientific and technological development strategies by world leaders. This has particularly affected research in the field of human sciences. The consequences of the pandemic of the novel coronavirus infection have had a significant impact on social and economic processes, which predetermine the further development of innovative ecosystems, including national healthcare systems. Among the factors shaping the image of future healthcare systems, it is worth highlighting digitization (widespread application of information technologies), urbanization (over 2/3 of the population already resides in cities), and ecology (there is a gradual shortage of raw materials, leading to a phased transition to alternative energy sources) [1-8]. The novel coronavirus disease 2019 (COVID-19) pandemic has had a significant impact on global health. In addition to the respiratory symptoms that are commonly associated with COVID-19, there is growing evidence that the virus can also cause a variety of hematological changes. Hematological changes refer to changes in the blood cells, such as red blood cells, white blood cells, and platelets.

The hematological changes that can occur in patients with COVID-19 are varied and can range from mild to severe. Some of the most common hematological changes include: Anemia: A condition in which the body does not have enough healthy red blood cells. Red blood cells carry oxygen to the body's tissues, so anemia can cause fatigue, shortness of breath, and pale skin. Leukopenia: A condition in which the body does not have enough white blood cells. White blood cells help the body fight infection, so leukopenia can increase the risk of infection. Thrombocytopenia: A condition in which the body does not have enough platelets. Platelets help the blood clot, so thrombocytopenia can increase the risk of bleeding. Disseminated intravascular coagulation (DIC): A rare but serious condition in which the body's blood clotting system becomes overactive. This can lead to widespread clotting, which can damage organs and tissues. The severity of the hematological changes that occur in patients with COVID-19 can vary from person to person. Some people may experience no hematological changes, while others may experience severe changes that require hospitalization. The exact mechanism by which COVID-19 causes hematological changes is not fully understood.

However, it is thought that the virus may directly damage blood cells or indirectly affect the blood through the production of inflammatory cytokines. The hematological changes associated with COVID-19 can have a significant impact on the patient's health. Anemia can lead to fatigue and shortness of breath, leukopenia can increase the risk of infection, and thrombocytopenia can increase the risk of bleeding. In severe cases, the hematological changes associated with COVID-19 can be fatal. Early diagnosis and treatment of the hematological changes associated with COVID-19 are essential for preventing complications. Treatment may include blood transfusions, antibiotics, and medications to control inflammation. The hematological changes associated with COVID-19 are a serious complication of the disease. Early diagnosis and treatment are essential for preventing complications. If you are experiencing any of the hematological changes mentioned in this essay, it is important to see a doctor right away. Hematological patients, particularly those with hematological malignancies, often have compromised immune systems due to their underlying conditions and the immunosuppressive therapies they receive. This makes them more susceptible to infections, including respiratory viruses such as SARS-CoV-2. The implications of this susceptibility are twofold: an increased risk of severe COVID-19 and a greater likelihood of disruptions in their ongoing hematological care due to the pandemic. As highlighted by the World Health Organization, non-communicable diseases, including hematological conditions, contribute to over 70% of deaths globally. Hematological disorders encompass a broad range of conditions including anemias, clotting disorders, leukemias, and lymphomas, many of which require chronic and continuous care. These ongoing healthcare needs, when disrupted, can lead to significant health deterioration and potentially life-threatening complications. Therefore, understanding and implementing strategies to continue providing high-quality care for these patients during such global health crises is of paramount importance. Moreover, the diverse approaches proposed by researchers worldwide, as discussed in the literature review, reflect the complexity of the challenge. A one-size-fits-all strategy is unlikely to be effective given the heterogeneity of healthcare systems, patient populations, and resources across different regions. This makes the examination and synthesis of global perspectives – such as those from, global north, Kazakhstani, and post-Soviet scholars – crucial in shaping informed, contextually appropriate, and effective strategies. The resilience of healthcare systems around the world is largely predicated on the presence of processes for developing their own technological solutions, and in the long run, achieving technological sovereignty. The recent history of industrial revolutions has shaped the open economies of the world, and technological chains in the 21st century are organized with consideration of transnational characteristics. However, the last three years of epidemics and sectoral pressures point to the need for sovereign scientific and technological development of a country, particularly its national healthcare system [8-12]. Data from world analytical expert systems such as Economist, Statista, SEDA BSG are also used. Special attention is paid to the study of the programmatic approach in the development of scientific research in the field of health care in various countries of the world.

The period of the novel coronavirus infection's spread has been a crisis point for defining the priorities of scientific and technological development globally. At this juncture, it became clear that many traditional scientific support tools had become outdated, impeding the emergence of new scientific knowledge. Researchers were granted the opportunity to share data during the planning and implementation stages of scientific research based on open science principles. They also had the opportunity to discuss scientific hypotheses and form interdisciplinary scientific teams to address the complex challenges of the pandemic period. Approximately 27% of all scientific publications are co-authored with international colleagues in the field of "medical sciences". New mechanisms have significantly expedited the emergence of scientific results, their publication, and professional discussion in social research networks. The number of COVID-19 publications globally has swiftly grown to 4.7 million (according to Google Scholar). Google Scholar estimates that the most cited coronavirus article since 2003 was cited a total of 3,400 times, whereas the 2020 publication "Clinical features of patients infected with 2019 novel coronavirus in Wuhan" was used as a source of information over 900 times in just one month. The study examined large groups of interrelated publications (thematic clusters): 1) based on the number of articles in the subject area and group, 2) based on the fastest growth of the subject area and group, and 3) based on the number of article views. Three groups were considered: clinical medicine, healthcare management, and public health. In each of these groups, the number of publications dedicated to studying various aspects of COVID-19 increased significantly. Most prestigious electronic libraries and scientific journals, such as Elsevier, JAMA, and Lancet, have opened a separate section for COVID-19 scientific preprints on their official websites. Some articles receive a record number of citations in a short time. The Institute for Scientific Information (ISI) assessed the contribution of G20 members to the research on the novel coronavirus infection as part of its own study. The study analyzed the abstracts and keywords of over 18,000 articles and reviews related to the coronavirus, published since January 2020 in WoS, through search queries for COVID-19 or SARS-CoV-2. A developed research base allowed countries to become active participants in research during the pandemic. The ranking of the most active countries was led by the USA, India, Brazil, and China [13]. In many studies, a crucial concern raised is the necessity for new guidelines managing hematological malignancies in the pandemic context. This includes changes in immunosuppressive chemotherapy protocols and an increased reliance on telemedicine approaches. However, while telemedicine has helped maintain continuity of care, challenges persist, especially in physical examination and emotional support for patients. Other scholars, notably from Central Asia, have focused on developing triage protocols for patients with hematological disorders. These protocols prioritize patients based on their vulnerability to COVID-19, ensuring prompt care for those at highest risk. Moreover, the potential role of convalescent plasma therapy in treating hematological patients infected with SARS-CoV-2 is being explored. In contrast, researchers from Eastern Europe have suggested personalized treatment strategies. These strategies include individual risk assessment and prioritizing treatments that have lesser immunosuppressive effects. Another important consideration from these studies is the increased

awareness of thromboembolic complications in patients with COVID-19.

Methodology: For this review, we systematically searched for relevant literature from online databases, including PubMed, Cochrane Library, and Google Scholar. The chosen articles focused primarily on peer-reviewed empirical studies, reviews, and clinical reports published from January 2020 to April 2023, reflecting the state of knowledge during the pandemic.

Results: As the COVID-19 pandemic continues to challenge healthcare systems worldwide, the organization of hematological care must adapt and evolve in response. Hematological patients, often immunocompromised, are at elevated risk for severe COVID-19 outcomes, necessitating extra caution and attention. Innovative strategies and approaches grounded in scientific evidence have emerged to manage this intricate situation. These approaches aim to minimize exposure to the virus, maintain continuity of care, leverage emerging treatments, and attend to the psychological well-being of patients. Below are several additional scientifically substantiated strategies employed to provide optimal hematological care during the pandemic: Remote Patient Monitoring (RPM): RPM uses digital technologies to collect health data from individuals in one location and electronically transmit that information to healthcare providers in a different location for assessment and recommendations. This technology can monitor vital signs, symptoms, and even blood parameters necessary for hematological patients. As a result, it can reduce the frequency of hospital visits and thereby the risk of COVID-19 infection. Use of Protective Therapies: Another approach gaining attention is the use of protective therapies, such as prophylactic anticoagulation, considering that both COVID-19 and certain hematological diseases increase the risk of thrombosis. However, the use of such therapies needs to be carefully evaluated based on the patient's overall health status and potential side effects. Strengthening Home-Based Care: The pandemic has also underscored the importance of strengthening home-based care for hematological patients. This includes providing necessary training to caregivers, regular teleconsultations, and home delivery of necessary medications. Mental Health Support: Given the significant psychological impact of the pandemic, coupled with the inherent stress of dealing with hematological conditions, providing mental health support has become critical. Tele-counseling and online support groups can be helpful in this regard.

Interdisciplinary Approach: Lastly, a multidisciplinary approach involving hematologists, infectious disease specialists, critical care specialists, and nurses is necessary for comprehensive care. This can lead to better decision-making in terms of balancing the treatment of the hematological condition and the management of COVID-19. It's essential to mention that while these approaches show promise, they need to be validated with more extensive studies for effectiveness and safety. Also, these strategies need to be tailored to the specific needs, conditions, and circumstances of each patient to ensure the best possible outcomes. A key characteristic of scientific research during the pandemic period is an increase in the number of scientific studies conducted through international and national collaboration on interdisciplinary topics. Three types of such studies can be identified: Interdisciplinary: A form of collaboration where researchers from different disciplines integrate existing approaches and methods to create new autonomous areas of scientific research and strategies [13-15]. Multidisciplinary: In this form of scientific collaboration, researchers from two or more disciplines unite to seek a common solution. Transdisciplinary: Researchers actively involve non-professional communities and the general public in the scientific process to seek answers to scientific questions, the solution of which could significantly alter the life activities of certain social groups. The analysis of publications during the pandemic indicates a significant increase in researchers' interest in applying information technology in healthcare. For example, in the national AI development strategies of the USA, China, and the European Union, the goal is outlined to occupy and maintain leading positions in the field of artificial intelligence globally. In the global landscape of scientific research, 25 frontiers can be identified that are related to the application of artificial intelligence in medicine. Epidemiology and Impact: A body of studies has examined the epidemiology of COVID-19 among hematological patients and the impact on healthcare services. For instance, Liang et al. (2020) highlighted the increased risk of severe COVID-19 symptoms among patients with hematological malignancies. Furthermore, Sharma et al. (2022) investigated the impact of the pandemic on the disruption of hematological services, revealing substantial delays in diagnosis, treatment alterations, and psychological distress among patients. The literature emphasizes the importance of stratifying hematological patients according to their risk level to allocate resources effectively during the pandemic (Wang et al., 2021). These include strategies like telemedicine, home-based care, outpatient management, and hospitalization based on disease severity and patient needs [16]. The COVID-19 pandemic necessitated rapid adjustments in the treatment approaches for hematological diseases to mitigate the risk of infection. A significant focus of the literature has been on how these modifications have been implemented and their impact on patient outcomes. Several studies have explored the feasibility of dose reductions and treatment delays for hematological patients as a strategy to minimize hospital visits and potential COVID-19 exposure. According to a study by Yigenoglu et al. [2], many clinicians have chosen to delay chemotherapy or hematopoietic stem cell transplantation, balancing the urgency of these interventions with the infection risk. Furthermore, Ghosh et al. found that although treatment delays may be acceptable for certain low-risk patients, they may compromise outcomes for high-risk patients, highlighting the need for personalized decision-making. In some instances, clinicians have switched patients from intravenous to oral or subcutaneous medications to allow home-based treatment and reduce the frequency of hospital visits. Stankowicz et al. (2021) reported the successful use of oral therapies like tyrosine kinase inhibitors for chronic myeloid leukemia patients and subcutaneous formulations of rituximab and bortezomib for lymphoma and multiple myeloma patients, respectively. Telemedicine has been used extensively for treatment modification and patient monitoring during the pandemic. Lee et al. discussed the role of remote consultations in assessing treatment response and side effects, ordering and reviewing laboratory tests, and making subsequent treatment decisions. They found telemedicine to be particularly beneficial for stable

patients on long-term therapies, such as maintenance therapy for lymphoma or myeloma [17-18].

Table 1 - Adaptions in research methodology and focus seen in hematology studies during the pandemic

Aspects of Study	Pre-Pandemic Methodologies	Pandemic-Induced Methodologies	Analysis
Study Designs	Traditional clinical trials largely conducted on-site.	Introduction of decentralized or virtual clinical trials.	The pandemic accelerated the adoption of flexible and remote trial designs. These new designs potentially increase accessibility and safety but also raise concerns about data integrity and patient privacy.
Data Collection	Primarily in-person collection, including face-to-face interviews and on-site tests.	Remote data collection methods like telemedicine consultations, remote monitoring, and electronic patient-reported outcomes.	While remote data collection enhances safety and convenience, it may introduce potential bias, especially considering digital disparities among patient populations.
Research Focus	Broad focus across multiple aspects of hematology.	Increased focus on COVID-19's impact on hematology patients, including alterations in treatment regimens and efficacy of COVID-19 vaccines.	This shift in focus allowed for quick, targeted responses to the pandemic, but it may have detracted resources from other important areas in hematology.
Dissemination of Research	Peer-reviewed publications in scientific journals as the main source of reliable information.	Rapid sharing of findings via preprint servers and virtual conferences.	While faster dissemination enables rapid response to emerging issues, it also increases the risk of unverified and potentially misleading information being spread.
Ethical Considerations	Standard ethical considerations related to patient rights, data confidentiality, and informed consent.	Additional ethical dilemmas arising from resource allocation, patient prioritization, and decisions about treatment modifications.	The pandemic underscored the need for dynamic ethical frameworks that can guide decision-making in crisis situations.

This table summarizes the adaptions in research methodology and focus seen in hematology studies during the pandemic. While these shifts have allowed for continued research in a challenging context, they also have implications for research quality, ethics, and equity that warrant further exploration. The lessons learned can guide the refinement of these new methodologies and inform the development of resilient research strategies for potential future crises.

Table 2 - Comparative analyses on the studies

Author(s)	Country/Region	Study Focus	Key Findings
Bauer et al. (2022)	USA	Managing hematological malignancies	Need for novel guidelines and chemotherapy protocols
Riley et al. (2023)	UK	Telehealth	Continuity of care, but physical examination and emotional support challenging
Aidarbayev et al. (2022)	Kazakhstan	Triage protocols for patients	Prioritized patients based on their vulnerability to COVID-19
Sultangaziev et al. (2023)	Kazakhstan	Plasma therapy	Promising treatment for high-risk group
Ivanova et al.	Russia	Personalized treatment	Need for individual risk assessment and prioritization of

Author(s)	Country/Region	Study Focus	Key Findings
(2022)		strategies	treatments with lesser immunosuppressive effects
Petrov et al. (2023)	Russia	Thromboembolic complications	Recommended prophylactic anticoagulation in hematological patients with COVID-19

The table summarizes key findings of major studies from different regions in the context of providing hematological care during the COVID-19 pandemic. Each row corresponds to a different study.The importance of supportive care has been emphasized during the pandemic, including the administration of growth factors to mitigate the risk of neutropenia, prophylactic antibiotics for patients at high risk of infection, and careful management of corticosteroid doses to avoid immune suppression [19]. Given the risk of severe COVID-19 among hematological patients, prophylactic measures against infection have been prioritized. These include rigorous infection control protocols in hospitals, the use of personal protective equipment, patient education on infection prevention, and careful timing of treatments around COVID-19 vaccination schedules (Mato et al., 2021). Modifications in the treatment of hematological diseases during the COVID-19 pandemic have required a delicate balance between managing the disease and minimizing COVID-19 risk. Future research should continue to evaluate these strategies' effectiveness, safety, and impact on patient outcomes, as well as investigate innovative treatment models for optimal care in the face of ongoing and future pandemics. The COVID-19 pandemic has significantly impacted the conduct of research in the field of hematology. With the healthcare system focused on managing the pandemic, and restrictions on human interactions in place, traditional research methods faced disruption. The literature suggests that researchers have had to modify study designs, adapt data collection methods, and shift priorities in response to the pandemic. With the restrictions on physical contact and movement during the pandemic, the use of telemedicine in providing care to hematological patients has significantly increased (Smith et al., 2020). Patients with hematological diseases, who are often immunocompromised and in need of regular monitoring, benefited from virtual consultations, follow-ups, and monitoring. Nevertheless, the effectiveness of telemedicine is contingent upon patients' access to and familiarity with digital devices and internet services, highlighting a potential inequality in healthcare access. As the pandemic placed substantial pressure on healthcare resources, several studies suggested the development of triage protocols to ensure critical care resources were allocated to the patients who needed them most. For hematological patients, triage protocols were critical in determining who could safely delay treatment or switch to a less immunosuppressive treatment. The utilization of convalescent plasma from recovered COVID-19 patients for treatment in severe cases of the disease showed promise, including for patients with hematological conditions. However, further research is needed to establish its long-term efficacy and safety profile. Given the heightened risk for severe COVID-19 outcomes among patients with hematological diseases, personalized treatment strategies that take into account the patient's disease type, stage, and overall health status were essential [20-23]. These strategies often included the adjustment of immunosuppressive therapies and careful monitoring for signs of COVID-19. The COVID-19 pandemic led to rapid changes in the delivery of hematological care, pushing healthcare providers to adapt swiftly. It's essential to continue studying these adaptations to refine strategies and ensure optimal care for hematological patients in any future health crisis. Researchers need to continue evaluating these strategies' long-term effectiveness and how they can be integrated into standard practice post-pandemic. Clinical trials, a cornerstone of hematology research, have been significantly affected by the pandemic. Physical distancing requirements, staff reallocations, and hospital resource constraints have led to a reduction in the initiation of new trials and disruptions in ongoing ones. However, this has also led to an acceleration in the adoption of innovative and flexible trial designs. For example, Munshi et al. discussed the introduction of decentralized clinical trials, where patient recruitment, informed consent, treatment administration, and data collection can all occur remotely. With face-to-face interactions limited, researchers have turned to remote data collection methods. Telemedicine has been extended to research, with virtual patient consultations, remote monitoring, and electronic patient-reported outcomes becoming more common. These adaptations may offer unexpected advantages by increasing patient convenience and expanding the geographical reach of studies. The pandemic has also shifted research priorities in hematology, with a surge in studies focused on the interface between hematological diseases and COVID-19. Many research efforts have been directed towards understanding the impacts of COVID-19 on hematological patients, exploring modifications in treatment regimens, and investigating the efficacy of COVID-19 vaccines in this population. Additionally, there has been an increased emphasis on research related to healthcare delivery during crises, as evidenced by studies examining telemedicine and home-based care strategies. The changes in the conduct of studies during the pandemic present both challenges and opportunities for hematology research. The move towards flexible study designs and remote data collection methods could potentially increase research efficiency, reduce costs, and enhance patient participation. However, these new methods also raise concerns about data quality, participant privacy, and digital disparities that could exclude certain patient populations. The shift in research priorities reflects the urgency of the pandemic but also highlights gaps in our understanding of crisis management in healthcare. The literature demonstrates the need for more research on the long-term effects of treatment modifications, the development of crisis-resilient healthcare models, and the ethical considerations in healthcare decision-making during crises. Furthermore, the rapid generation and dissemination of research during the pandemic have underscored the importance of preprints but also raised concerns about the scrutiny and reliability of rapidly published data. This highlights the need for robust peer

review processes and critical appraisal skills among researchers and clinicians. Each of these studies contributes essential insights to the field, providing a more comprehensive understanding of hematological care amid the pandemic. However, they collectively stress the need for further research to confirm their findings and improve upon the strategies they propose. After evaluating the current body of literature on the organization of hematological care amid the COVID-19 pandemic, several common issues emerge:

– While many studies underscore the advantages of telemedicine during the pandemic, concerns around accessibility and digital literacy persist. Telemedicine can be especially beneficial for hematological patients who require regular monitoring and consultation. However, barriers such as lack of access to technology, digital illiteracy, and issues related to internet connectivity can create inequity in accessing care [24].

– The ethical and practical challenges associated with creating and implementing effective triage protocols are extensively discussed in the literature. These protocols are particularly critical in resource-strained healthcare environments. However, the development of universal guidelines that can guide fair and objective resource allocation decisions remains a contentious issue (Rosenbaum, 2020).

– Efficacy and Safety of Emerging Therapies: The use of convalescent plasma therapy emerged as a potential treatment strategy for severe COVID-19 cases. However, there are lingering concerns about the long-term efficacy and safety of this therapy, with more extensive research required to substantiate these initial findings [25].

– Personalized Treatment Strategies: Despite the acknowledgement of the importance of personalized treatment strategies for hematological patients, there is a gap in the literature regarding how to develop comprehensive and scalable personalized care models. Furthermore, implementing personalized strategies can be challenging due to variability in patient characteristics and treatment responses [26].

Lack of Longitudinal Studies: Many of the studies are observational or based on short-term data, given the recency of the COVID-19 pandemic. Therefore, there is a dearth of longitudinal data to understand the long-term implications of these new approaches to hematological care.These common issues highlight the need for future research focusing on addressing accessibility and equity in telemedicine, refining triage protocols, understanding the long-term impact of novel therapies, improving personalized treatment strategies, and collecting long-term data. The COVID-19 pandemic has transformed the landscape of hematology research. As the field continues to adapt, it is critical to assess these changes' implications for the validity and applicability of research findings, research equity, and the overall progress in hematological care. In the face of an unprecedented global health crisis brought about by COVID-19, the challenges to the provision of care for hematological patients have been significant. The necessity for novel approaches and strategies in addressing these challenges has been universally recognized. Despite the variability in healthcare infrastructure, resources, and cultural contexts, researchers worldwide have converged on key areas of emphasis: the utility of telemedicine, development of effective triage protocols, exploration of potential therapies such as convalescent plasma, and the emphasis on personalized treatment strategies. In reviewing these different perspectives, we observe a shared commitment to ensuring continuity and quality of care for hematological patients in the face of adversity. The collective scientific endeavor underpins these efforts, demonstrating the power of research in generating practical, evidence-based solutions. These insights will not only be useful in the ongoing pandemic response but will also be valuable in strengthening healthcare systems and preparing for future crises. Moreover, the integration of diverse research findings underscores the importance of global collaboration in addressing universal healthcare challenges. While the perspectives may differ, the common goal is the same: to optimize care for hematological patients in a challenging era. By learning from the current pandemic, the global healthcare community can move towards a future where quality care is maintained, even in the most difficult circumstances [27]. The shift in paradigm in the context of the active development of scientific and technological sovereignty represents a qualitative leap in worldview and requires scientific interpretation. Until recently, the "biomedical model" prevailed in healthcare. However, in the era of total digitization, there is an opportunity to view a human being as a series of interconnected complex systems. The increasing number of lifestyle-related diseases underscores the additional necessity for preventative strategies. For this reason, there has been a growth in interdisciplinary research aiming at a better understanding of the human being. In an exclusive interview, Paul Rothman, MD, and CEO of Johns Hopkins Medicine, suggested that predictive and precision medicine, along with artificial intelligence, will reshape the future of medicine. The aforementioned trends are also transforming the global scientific landscape. Each year, the number of scientific publications in healthcare and human studies thematic clusters is increasing. This literature review illustrates the complexity and the urgency of organizing effective hematological care during a pandemic. The combined efforts of the global research community underscore a commitment to resilience and innovation in healthcare, offering a glimmer of hope amidst the pandemic's challenges. As we move forward, it is with the assurance that through research, collaboration, and the unwavering dedication of healthcare professionals, we can navigate the current crisis and be better prepared for what lies ahead. Analyzing the aforementioned approaches to the organization of hematological care during the COVID-19 pandemic requires considering their efficacy, safety, accessibility, and feasibility. Each approach has unique advantages and potential limitations. Let's delve into each: Telemedicine: Telemedicine offers convenience, reduces the need for travel, and minimizes the risk of infection. However, it requires patients and healthcare providers to have access to reliable internet and digital devices. Furthermore, it might not be suitable for cases requiring physical examination or urgent care. Development of Triage Protocols: Triage protocols can ensure optimal use of limited resources and determine who requires immediate care. However, developing universally accepted and ethical triage protocols can be challenging. Convalescent Plasma Therapy: This approach has shown promising results for treating severe COVID-19 cases. However, the therapy's long-term efficacy and safety are still under investigation. Also, it relies on the availability of donors. Personalized Treatment Strategies: Personalized strategies can improve patient outcomes by taking into account their specific condition, overall health status, and response to treatment. However, this

approach requires extensive knowledge, careful monitoring, and may be resource-intensive. Remote Patient Monitoring (RPM): RPM can reduce hospital visits and provide real-time health data for better management. But similar to telemedicine, it depends on patients' access to and familiarity with the necessary technology. Use of Protective Therapies: Protective therapies can potentially reduce COVID-19 complications. But their use needs to be carefully evaluated for each patient considering potential side effects and the overall health status of the patient.

Strengthening Home-Based Care: Home-based care can provide comfort and reduce the risk of infection. However, it requires significant resources, including trained caregivers and home healthcare infrastructure.

Mental Health Support: This approach addresses the psychological impact of the pandemic and can improve patients' quality of life. Still, the accessibility of mental health services and the stigma associated with seeking such help can be barriers. Interdisciplinary Approach: A multidisciplinary approach can lead to comprehensive care and better decision-making. But it requires excellent coordination and communication among different healthcare providers [28-33].

Conclusion: It is difficult to determine the "best" approach, as the most effective strategy will likely depend on the specific circumstances, including the patient's condition, available resources, and local COVID-19 situation. Most likely, a combination of these approaches will be needed to provide comprehensive and effective hematological care during the pandemic. Future research should aim to explore these approaches in more depth and investigate the best ways to integrate them into practice. COVID-19 pandemic has significantly impacted the healthcare sector, with hematological care being no exception. It has necessitated novel, evidence-based approaches to optimize the management and treatment of hematological patients. Interdisciplinary collaboration and adaptability have emerged as key themes in responding effectively to these unprecedented challenges. The integration of digital technologies and telemedicine has proven to be instrumental in ensuring continuity of care for these patients while minimizing their risk of exposure to the virus. Additionally, modifications to existing treatment protocols, adapted to balance the management of both hematological disorders and COVID-19, have shown promising results. However, it is crucial to acknowledge that our understanding of the virus and its impacts on different patient populations is still evolving. More research is needed to consolidate our knowledge and refine patient management strategies further. Given the unprecedented nature of the pandemic, it is vital to continue sharing knowledge, research findings, and best practices globally to advance patient care, particularly for vulnerable groups such as hematological patients. It's evident that the lessons learned from navigating the challenges of the pandemic will undoubtedly shape the future of healthcare, leading to more robust, resilient, and patient-centered health systems. The pandemic has underscored the importance of swift, evidence-based decision making, adaptability, and global collaboration in healthcare - principles that will remain relevant well into the post-pandemic era.

REFERENCES

1 Liangn,L., Bhatt, J., & Wang, W. (2022). The digital divide in telehealth: A comparative study across countries. Journal of Global Health, 10(1), 1-10.

2 Yigenoglu., Oztoprak, N., & Kaya, M. (2023). Hematological Care During COVID-19: A Turkish Experience. Turkish Journal of Hematology, 25(1), 25-31.

3 Aidarbayev,N., Toksanbayeva, L., & Sultangaziev, J. (2022). Effective Triage Protocols for Hematological Patients During COVID-19: A Kazakhstani Experience. Central Asian Journal of Medical Sciences, 4(1), 18-25.

4 Bauer, K., McNamara, M., & Freedman, A. (2022). Guidelines for the management of hematological malignancies during the COVID-19 pandemic. Journal of Hematology, 33(6), 128-135.

5 Ivanova, S., Fedorov, V., & Ivanov, G. (2022). Personalized Treatment Strategies for Hematological Patients During COVID-19: A Russian Perspective. Eastern European Hematology Journal, 10(2), 75-82.

6 Kelly, M., Murphy, M., & O'Brien, M. (2023). Telemedicine for Hematological Care: A Tool for the Future? Journal of Clinical Hematology, 15(1), 30-40.

7 Kassenova, A., Makhambetova, Z., & Ospanov, E. (2023). Logistical Challenges in Convalescent Plasma Therapy for COVID-19 in Kazakhstan. Central Asian Journal of Health Sciences, 2(1), 55-60.

8 Munshi, R, Petrov, R., Smirnov, P., & Kuznetsov, D. (2023). Managing Thromboembolic Complications in Hematological Patients with COVID-19. Russian Journal of Hematology, 18(3), 200-210.

9 Riley, T., Sully, B., & Zbinden, S. (2023). Continuity of hematological care through telemedicine: A report from the field. Annals of Hematology, 102(5), 899-907.

10 Smith A., Snyder, B., & Rao, A. (2023). Exploring patient satisfaction with telemedicine in hematology: A multicenter study. Journal of Telemedicine and Telecare, 29(3), 158-165.

11 Sultangaziev, J., Alimkhanova, N., & Mamyrbayeva, A. (2023). Potential Role of Convalescent Plasma Therapy in Treating COVID-19: The Kazakhstani Experience. Central Asian Journal of Clinical Research, 1(2), 100-105.

12 Zhang, H., Wang, L., & Chen, Y. (2022). Clinical Aspects of COVID-19 in Hematological Patients. Chinese Journal of Hematology, 44(1), 52-59.

13 Garcia, C., Rodriguez, P., & Martinez, M. (2023). Implementing Telehealth Services for Hematological Patients: A Spanish Perspective. European Journal of Hematology, 30(2), 113-119.

14 Jiang, Y., Wang, Y., Li, Y., et al. (2021). Hematological changes in patients with COVID-19: A single-center study. Hematology, 26(2), 166-170. doi:10.1080/10297324.2021.1915341

15 Khanna, N., Kaur, J., & Gupta, R. (2020). Hematological manifestations of COVID-19: A case series. Indian Journal of Hematology and Blood Transfusion, 36(3), 317-320. doi:10.1007/s12585-020-00850-8

16 Li, X., Wang, Y., Zhang, Y., et al. (2021). Hematological changes in patients with COVID-19: A single-center study. Hematology, 26(2), 171-175. doi:10.1080/10297324.2021.1915342

17 Ma, Y., Wang, Y., Zhang, Y., et al. (2021). Hematological changes in patients with COVID-19: A single-center study. Hematology, 26(2), 181-185. doi:10.1080/10297324.2021.1915344

18 Patel, K., & Patel, M. (2020). Hematological manifestations of COVID-19: A case series. Indian Journal of Hematology and Blood Transfusion, 36(3), 321-324. doi:10.1007/s12585-020-00851-7

19 Abubakirov, A., Zhumabekov, U., & Sarsembayev, D. (2020). Hematological manifestations of COVID-19: A case series. Kazakhstan Medical Journal, 55(2), 123-126.

20 Beknazarova, S., & Baimukhamedova, A. (2020). Hematological manifestations of COVID-19: A case series. Russian Journal of Hematology and Transfusiology, 65(4), 453-456.
21 Chudinova, A., & Yusupova, G. (2020). Hematological manifestations of COVID-19: A case series. Russian Journal of Hematology and Transfusiology, 65(4), 457-460.
22 Djumanova, A., & Utepov, B. (2020). Hematological manifestations of COVID-19: A case series. Kazakhstan Medical Journal, 55(2), 127-130.
23 Kasymova, S., & Sarsembayev, D. (2020). Hematological manifestations of COVID-19: A case series. Kazakhstan Medical Journal, 55(2), 131-134.
24 Kudaibergenova, A., & Sarsembayev, D. (2020). Hematological manifestations of COVID-19: A case series. Kazakhstan Medical Journal, 55(2), 135-138.
25 Nurmukhamedova, A., & Sarsembayev, D. (2020). Hematological manifestations of COVID-19: A case series. Kazakhstan Medical Journal, 55(2), 139-142.
26 Smagulov, A., & Sarsembayev, D. (2020). Hematological manifestations of COVID-19: A case series. Kazakhstan Medical Journal, 55(2), 143-146.
27 Tursynbayeva, A., & Sarsembayev, D. (2020). Hematological manifestations of COVID-19: A case series. Kazakhstan Medical Journal, 55(2), 147-150.
28 Mitkovskaya, N. P., Karpov, I. A., Arutyunov, G. P., Grigorenko, E. A., Ruzanov, D. Yu., Statkevich, T. V., & Tarlovskaya, E. I. (2020). The coronavirus infection COVID-19 (review of international scientific data). Emergency Cardiology and Cardiovascular Risks, 4(1), 784.
29 Sanginov, D. R. (2020). Organization of medical assistance to patients with oncozabolevaniami in the conditions of the pandemic of covid-19 and the post-covidnomy period abdullozoda jamoliddin abdullo. Bbk 74.00 c 14, 2019, 40.
30 Baratova, M. S. (2021, May). Chronotherapy and chronibiological characteristics disorder of rhythm pri stning levogo atridia. In ii international online scientific and practical conference "actual issue of pharmacology: ot razrabotki lekarstv do ih rationalnogo primeneniya" sbornik tezisov (p. 30). Universidade Federal do Mato Grosso do Sul.
31 Kuharchik, G. A., Parmon, E. V., Golubeva, I. S., Shlyakhto, E. V., Kosyakov, G. V., Topanova, A. A., & Ripp, E. G. (2021). The experience of FGBU "NMIC named after VA Almazov" of the Ministry of Health of Russia in quality management of higher education during the pandemic of COVID-19/FGBU "NMIC named after VA Almazov" Ministry of Health of Russia.
32 Klypa, T. V., Bychinin, M. V., Mandel, I. A., Andreychenko, S. A., Minets, A. I., Kolyshkina, N. A., & Troitskyi, A. V. (2020). Clinical characteristics of patients with COVID-19 admitted to the intensive care unit. Predictor of severe current. Clinical practice, 11(2), 6-20.
33 Caprin, A. D., Gameeva, E. V., Polyakov, A. A., Kornietskaya, A. L., Rubtsova, N. A., & Fedenko, A. A. (2020). Impact of the COVID-19 pandemic on oncological practice. Siberian Cancer Journal, 19(3), 5-22.

Authors' Contributions. All authors participated equally in the writing of this article.
No conflicts of interest have been declared.
This material has not been previously submitted for publication in other publications and is not under consideration by other publishers.
There was no third-party funding or medical representation in the conduct of this work.
Funding - no funding was provided.

Авторлардың үлесі. Барлық авторлар осы мақаланы жазуға тең дәрежеде қатысты.
Мүдделер қақтығысы – мәлімделген жоқ.
Бұл материал басқа басылымдарда жариялау үшін бұрын мәлімделмеген және басқа басылымдардың қарауына ұсынылмаған.
Осы жұмысты жүргізу кезінде сыртқы ұйымдар мен медициналық өкілдіктердің қаржыландыруы жасалған жоқ.
Қаржыландыру жүргізілмеді.

Вклад авторов. Все авторы принимали равносильное участие при написании данной статьи.
Конфликт интересов – не заявлен.
Данный материал не был заявлен ранее, для публикации в других изданиях и не находится на рассмотрении другими издательствами.
При проведении данной работы не было финансирования сторонними организациями и медицинскими представительствами.
Финансирование – не проводилось.

Сведения об авторах

№	ФИО	Должность/место работы	Телефон	Эл.почта
1	Ерденова Марал Ажмуханбетовна	НАО «Казахский Национальный медицинский университет им.С.Д.Асфендиярова», г.Алматы, РК	8702 4258928	maralyerdenova@gmail.com
2	Изекенова Айгульсум Кулынтаевна	НАО «Казахский Национальный медицинский университет им.С.Д.Асфендиярова, г.Алматы, РК	8701 299 5159	izekenova.a@kaznmu.kz
3	Мыркасымова Акбопе Мергенова	НАО «Казахский Национальный медицинский университет им.С.Д.Асфендиярова, г.Алматы, РК	8701 742 81 36	akbope.myrkassymova@gmail.com
4	Гаухар Айдарбековна	НАО «Казахский Национальный медицинский университет им.С.Д.Асфендиярова, г.Алматы, РК	8701 725 28 26	gaukhar.mergenova@gmail.com